WallStreetZenWallStreetZen

NASDAQ: EVAX
Evaxion Biotech A Stock

Overview
ForecastEarningsDividendOwnership
$4.12-0.01 (-0.24%)
Updated Apr 25, 2024
EVAX Price
$4.12
Fair Value Price
-$1.72
Market Cap
$15.61M
52 Week Low
$2.82
52 Week High
$18.50
P/E
-0.51x
P/B
-3.3x
P/S
259.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$73.00k
Earnings
-$22.13M
Gross Margin
100%
Operating Margin
-29,087.67%
Profit Margin
-30,308.2%
Debt to Equity
-3.73
Operating Cash Flow
-$18M
Beta
0.51
Next Earnings
May 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A

EVAX Overview

Evaxion Biotech A/S develops novel immunotherapies to treat various cancers, bacterial diseases, and viral infections suing proprietary AI platforms (PIONEER, EDEN, and RAVENTM). The company's drug candidates include EVX-01, EVX-02, and EVX-03. Evaxion Biotech A/S has collaboration agreements with the National Center at Herlev Hospital, the Department of Health Technology at Danish Technical University, and other institutions. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EVAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

EVAX ($4.12) is overvalued by 339.01% relative to our estimate of its Fair Value price of -$1.72 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
EVAX ($4.12) is not significantly undervalued (339.01%) relative to our estimate of its Fair Value price of -$1.72 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EVAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EVAX due diligence checks available for Premium users.

Be the first to know about important EVAX news, forecast changes, insider trades & much more!

EVAX News

Valuation

EVAX fair value

Fair Value of EVAX stock based on Discounted Cash Flow (DCF)
Price
$4.12
Fair Value
-$1.72
Undervalued by
339.01%
EVAX ($4.12) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EVAX ($4.12) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EVAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

EVAX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.51x
Industry
15.41x
Market
40.97x

EVAX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-3.3x
Industry
5.8x

EVAX's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
EVAX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EVAX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$12.9M
Liabilities
$17.6M
Debt to equity
-3.73
EVAX's short-term assets ($8.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVAX's long-term liabilities ($10.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVAX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EVAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
EVAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

EVAX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
EVAX$15.61M-0.24%-0.51x-3.30x
CDIO$15.59M-3.73%-1.09x5.27x
AVTX$15.49M+5.49%-0.13x2.12x
ADXN$15.43M-0.90%-98.78x12.13x
COCP$15.36M-2.96%-0.81x0.58x
View Top Biotech Stocks

Evaxion Biotech A Stock FAQ

What is Evaxion Biotech A's quote symbol?

(NASDAQ: EVAX) Evaxion Biotech A trades on the NASDAQ under the ticker symbol EVAX. Evaxion Biotech A stock quotes can also be displayed as NASDAQ: EVAX.

If you're new to stock investing, here's how to buy Evaxion Biotech A stock.

What is the 52 week high and low for Evaxion Biotech A (NASDAQ: EVAX)?

(NASDAQ: EVAX) Evaxion Biotech A's 52-week high was $18.50, and its 52-week low was $2.82. It is currently -77.73% from its 52-week high and 45.89% from its 52-week low.

How much is Evaxion Biotech A stock worth today?

(NASDAQ: EVAX) Evaxion Biotech A currently has 37,897,780 outstanding shares. With Evaxion Biotech A stock trading at $4.12 per share, the total value of Evaxion Biotech A stock (market capitalization) is $15.61M.

Evaxion Biotech A stock was originally listed at a price of $98.90 in Feb 5, 2021. If you had invested in Evaxion Biotech A stock at $98.90, your return over the last 3 years would have been -95.83%, for an annualized return of -65.33% (not including any dividends or dividend reinvestments).

How much is Evaxion Biotech A's stock price per share?

(NASDAQ: EVAX) Evaxion Biotech A stock price per share is $4.12 today (as of Apr 25, 2024).

What is Evaxion Biotech A's Market Cap?

(NASDAQ: EVAX) Evaxion Biotech A's market cap is $15.61M, as of Apr 27, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Evaxion Biotech A's market cap is calculated by multiplying EVAX's current stock price of $4.12 by EVAX's total outstanding shares of 37,897,780.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.